Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse

Bachar Samra,1,* Joseph D. Khoury,2 Kiyomi Morita,1,* Farhad Ravandi,1 Guillaume Richard-Carpentier,1 Nicholas J. Short,1 Siba El Hussein,2 Philip Thompson,1 Nitin Jain,1 Hagop Kantarjian,1 and Elias Jabbour1

1Department of Leukemia and 2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Burdick leukemia/lymphoma (BL) and high-grade B-cell lymphoma (HGBL) have a high incidence of central nervous system (CNS) involvement, which is associated with poor prognosis. The hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen includes systemic and intrathecal CNS-directed therapy to treat and prevent CNS disease. We report here the long-term safety and efficacy of the hyper-CVAD-R regimen in adults with BL and HGBL, focusing on its efficacy to prevent CNS relapse. Among 79 adults (54 BL, 25 HGBL), the median age was 44 years (25% ≥ 60 years old), 73% had bone marrow (BM) involvement, and 28% had CNS involvement. The complete response rate was 91% (BL 96%; HGBCL 79%; P = .16). The 5-year relapse-free survival (RFS) and overall survival (OS) rates were 58% and 52%, respectively. The cumulative incidence of relapse (CIR) was 21% (BL 14%; HGBCL 37%; P = .06) and was associated with baseline BM (27% vs 0%; P = .02) and CNS (42% vs 12%; P < .01) involvement. In multivariate analyses, age and CNS involvement were independent predictors for OS and RFS. The 5-year CNS CIR was 6% (BL 4%; HGBL 11%; P = .31); 16% with baseline CNS involvement (P = .03). Our data support the use of hyper-CVAD-R in preventing CNS relapse, especially among high-risk patients with BM or CNS involvement.

Introduction

Burdick leukemia/lymphoma (BL) and high-grade B-cell lymphoma (HGBL, previously “atypical Burkitt lymphoma”) are aggressive lymphomas that share similar histologic and biologic features with high risk of central nervous system (CNS) involvement.1-4 The standard of care for BL is dose-intense chemoimmunotherapy regimens with rituximab and CNS-directed therapy such as high-dose methotrexate (MTX) and cytarabine (Ara-C).5-8 The optimal management of HGBL remains uncertain.9 The dose-adjusted (DA)-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) regimen was developed to increase efficacy in proliferative lymphoid neoplasms while limiting toxicity associated with BL-like chemoinmunotherapy regimens. It showed favorable efficacy and tolerability in patients with aggressive lymphomas, including HGBL and BL, without improvement of outcomes in patients with diffuse large B-cell lymphoma when compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.10-12 The DA-EPOCH-rituximab (EPOCH-R) regimen does not include systemic CNS-directed therapy and therefore may not be suitable for patients at higher risk of CNS relapse, such as those with baseline bone marrow (BM) or CNS involvement.9,13,14 In contrast, the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen includes 4 cycles of high-dose MTX and Ara-
C and a total of 16 intrathecal (IT) chemotherapy. Here, we report the long-term safety and efficacy of the hyper-CVAD-R in patients with BL and HGBCL focusing on patterns of relapse.

**Methods**

Between January 2000 and January 2018, 102 patients with newly diagnosed BL or HGBCL treated with the hyper-CVAD-R regimen were retrospectively reviewed. Patients provided informed consent according to MD Anderson Cancer Center guidelines after approval by the institutional review board. Eligibility criteria included age ≥15 years and Eastern Cooperative Oncology Group (ECOG) performance status ≤3 with no restrictions for older age, organ dysfunction, or presence of HIV. Because the diagnostic criteria of HGBCL have undergone recent changes, all cases were reviewed retrospectively (J.D.K. and S.E.H.) to confirm that they meet current diagnostic criteria according to the 2017 World Health Organization classification.15 Among 102 cases, 54 were confirmed BL, 25 were confirmed HGBCL, and 23 cases were excluded because they did not have sufficient information to be confirmed as BL or HGBCL.

The doses and schedule of hyper-CVAD-R were previously described.8,16,17 CNS prophylaxis consisted of 16 IT alternating doses of MTX/Ara-C. For patients with baseline CNS involvement, IT therapy was administered twice weekly until clearance, then weekly for 4 doses, after which prophylaxis was resumed. No routine cranial irradiation was administered.

We evaluated complete response (CR) rates, relapse-free survival (RFS), overall survival (OS), and cumulative incidence of relapse (CIR).

**Results**

The patient characteristics are shown in Table 1. No differences were observed between BL and HGBCL. The median age was 44 years; 25% were older than 60 years. Eleven patients (13%) were HIV-positive. Fifty-four patients (73%) had BM involvement and 22 (28%) had CNS disease (21 leptomeningeal and 1 parenchymal). Three patients received cranial radiation (1 for leptomeningeal disease and 2 for cranial nerve palsies). Among the 25 patients with HGBCL, 7 (28%) had double-hit lymphoma (with BCL2 rearrangement).

Among 75 evaluable patients, the CR rate was 91% (BL 96%; HGBCL 79%; \(P = .16\)) and the 30-day mortality was 3%. Death in CR occurred in 21 patients (28%, median age 56 [range, 22-77]). Most deaths in CR (76%) were treatment-related, primarily from infections (48%) and secondary myeloid malignancies (19%) (supplemental Table 1).

With a median follow-up of 50 months, 33 patients (42%) were alive in CR (23 BL, 10 HGBCL). Only 1 patient with relapsed disease (first CR [CR1] duration 6 years) remains alive in second CR (CR2) for 5+ years after salvage with DA-EPOCH-R. The 5-year OS and RFS rates were 52% (BL 55%; HGBCL 44%; \(P = .86\)) and 58% (BL 59%; HGBCL 57%; \(P = .62\)), respectively (Figure 1A-B). The 5-year OS and RFS rates were inferior in patients ≥60 years (OS 30% vs 59%, \(P < .01\); RFS 38% vs 65%, \(P < .01\), Figure 1C-D) and those with baseline CNS involvement (OS 23% vs 63%, \(P < .01\); RFS 26% vs 71%, \(P < .01\), Figure 1E-F). In patients aged <60 years with no CNS or BM involvement (n = 19; 10 BL and 9 HGBCL), the 5-year OS and RFS rates were 68% and 86%, respectively. Patients with higher BL International Prognostic Index had worse outcome: 5-year OS 83% vs 67% vs 42%; 5-year RFS 91% vs 80% vs 45% in patients with BL International Prognostic Index low vs intermediate vs high, respectively (supplementary Figure 1).

Multivariate analysis adjusted for age, ECOG performance status, lactate dehydrogenase, CNS disease, and HIV status showed that only age and CNS disease at baseline were independently associated with worse OS (\(P < .01\) for both) and RFS (\(P = .02\) and \(P < .01\), respectively). ECOG performance status was predictive of OS when the multivariate analysis was restricted to patients with CNS disease. The CIR was 21% (BL 14%; HGBCL 37%; \(P = .06\)) and was higher in patients with baseline BM (27% vs 0%; \(P = .02\) or CNS (42% vs 12%; \(P < .01\)) involvements (Figure 1G-H). The median time to relapse was 75 months (range, 0.5-228.1 months).

Four patients had CNS relapses (2 isolated parenchymal relapses, 2 leptomeningeal with systemic relapses) at a median of 5.6 months from diagnosis (range, 7.1-11.3). Three of them had baseline CNS disease. All 4 died of their disease at median of 2.5 months after CNS relapse. The 5-year CNS CIR disease was 6% (BL 4%; HGBCL 11%; \(P = .31\)). Baseline CNS involvement was the main factor associated with CNS relapse (\(P = .03\)). Of the 22 patients with CNS involvement at baseline, 3 had CNS relapse (1 isolated parenchymal, 2 leptomeningeal with systemic relapse). Eighteen of the 22 patients died, and the cause of death was disease (N = 10), infections (N = 5, all but 1 were in CR), toxicity (N = 1), and unknown (N = 2). Among the 22 patients with CNS involvement, multivariate analysis adjusting for age, ECOG performance status, lactate dehydrogenase, and HIV status showed that ECOG performance status was predictive of OS.

**Discussion**

This long-term follow-up of the hyper-CVAD-R regimen in BL and HGBCL supports the efficacy of dose-intensive regimens in preventing CNS relapses, especially among high-risk patients. Patients <60 years without CNS or BM disease had the best outcome (5-year OS, RFS and CIR rates of 68%, 86%, and 0%, respectively). When stratified by age and disease risk, our findings seem comparable to other previously reported regimens.6,7,14 Importantly, our cohort includes a population with high frequency of baseline CNS (28%) and BM (73%) involvement. In a recent report evaluating the DA-EPOCH-R regimen18 in 113 patients with BL, the median age was 38 years and the frequency of CNS and BM involvement at diagnosis was 10% and 28%, respectively, representing a lower risk population. In their study, the 4-year OS was 87% and the 4-year event-free survival was worse for patients with baseline CNS (46%) and BM (67%) involvement. Among 11 patients with baseline CNS disease, 6 either progressed (n = 3 including 1 with systemic and brain parenchyma) or died (n = 3). Two of 81 high-risk patients (2%) without baseline CNS involvement relapsed with parenchymal CNS disease despite IT chemotherapy (contrasting with no relapses in our BL cohort).

The low incidence of CNS relapses in our cohort is consistent with a recent study among 587 adults in newly diagnosed BL, where treatment with DA-EPOCH was associated with an increased risk of CNS relapse (CIR 13% vs 2% to 4% with dose-intensive regimens).19 In another retrospective study of 64 adults with BL (n = 38) or HGBCL (n = 26), the 1-year incidence of CNS relapse was 36% in patients treated with DA-EPOCH-R versus 0% in patients treated with dose-intensive regimens.20
These studies and our data support the use of high-dose MTX and Ara-C for patients with BL or HGBL at high risk of systemic and CNS relapse. A major limitation is the high risk of treatment-related toxicity and deaths in CR especially in patients older than 40 or 60 years. For these patients, future modification of induction therapy with hyper-CVAD-R in combination with blinatumomab and inotuzumab followed possibly by chimeric antigen receptor T-cell therapy are expected to further improve the outcome of patients with baseline or at higher risk for CNS disease. DA-EPOCH-R should possibly be reserved for patients with low-risk disease and those who may not tolerate more intensive regimens.

TREATING AND PREVENTING CNS DISEASE IN BL AND HGBL WITH HYPER-CVAD-R

Table 1. Characteristics and outcomes of patients with BL and HGBL treated with hyper-CVAD-R

| Characteristic                        | Total (n = 79) | BL (n = 54) | HGBL (n = 25) | P value |
|---------------------------------------|---------------|------------|--------------|---------|
| Age at Dx, y                          | 44 [18-77]    | 42 [18-77] | 47 [20-75]  | .24     |
| Age ≥60 y                             | 20 (25)       | 12 (22)    | 8 (32)       | .51     |
| Sex (male)                            | 51 (65)       | 36 (67)    | 15 (60)      | .75     |
| ECOG PS 0-1                           | 52/75 (69)    | 35/52 (67) | 17/23 (74)   | .76     |
| Stage 4                               | 70 (89)       | 49 (91)    | 21 (84)      | .67     |
| BM disease                            | 58 (73)       | 42 (78)    | 16 (64)      | .31     |
| Extramedullary disease                | 36 (46)       | 24 (44)    | 12 (48)      | .96     |
| CNS disease at Dx                     | 22 (28)       | 15 (28)    | 7 (28)       | 1.00    |
| Positive CSF                          | 16 (20)       | 11 (20)    | 5 (20)       | .51     |
| Parenchymal disease                   | 1 (2)         | 0          | 1 (4)        | .43     |
| Clinical manifestations               | 5 (6)         | 4 (8)      | 1 (4)        | .43     |
| LDH ≥3 ULN, n (%)                     | 50 (63)       | 38 (70)    | 12 (48)      | .10     |
| HIV-related                           | 11 (14)       | 9 (17)     | 2 (8)        | .49     |
| DHL NA                                | NA            | NA         | 7 (28)       |         |
| IPI NA                                | NA            | NA         | 3.5 [2-5]    |         |
| CNS-IPI NA                            | NA            | NA         | 3 [1-4]      |         |
| Treatment outcome, n (%)              |               |            |              |         |
| CR rate                               | 68/75 (91)    | 49/51 (96) | 19/24 (79)   | .16     |
| Early death <30 d                     | 2 (3)         | 2 (4)      | 0            | .84     |
| Early death <60 d                     | 5 (6)         | 4 (7)      | 1 (4)        | .93     |
| Relapse                               | 15/68 (22)    | 8/49 (16)  | 7/19 (37)    | .13     |
| CNS relapse                           | 4 (5)         | 2 (4)      | 2 (8)        | .43     |
| Isolated CNS relapse                  | 2 (50)        | 1 (50)     | 1 (50)       |         |
| Death                                 | 46 (58)       | 31 (57)    | 15 (60)      | 1.00    |
| Death in CR                           | 21 (27)       | 18 (33)    | 3 (12)       |         |
| Overall survival                      |               |            |              | .86     |
| Median, mo (95% CI)                   | 71 (18-NR)    | 125 (13-NR)| 25 (17-NR)   |         |
| 5-y, % (95% CI)                       | 52 (42-64)    | 55 (44-70) | 44 (28-68)   |         |
| Relapse-free survival                 |               |            |              | .62     |
| Median, mo (95% CI)                   | 127 (54-NR)   | 126 (50-NR)| NR (10-NR)   |         |
| 5-y, % (95% CI)                       | 58 (48-72)    | 59 (47-75) | 57 (39-85)   |         |
| Cumulative incidence of relapse       |               |            |              | .06     |
| 5-y, % (95% CI)                       | 21 (11-30)    | 14 (4-24)  | 37 (14-59)   |         |
| Cumulative incidence of CNS relapse   |               |            |              | .31     |
| 5-y, % (95% CI)                       | 6 (0-12)      | 4 (0-10)   | 11 (0-25)    |         |

Abbreviations: BM, bone marrow; CI, confidence interval; CNS, central nervous system; CR, complete response; CSF, cerebrospinal fluid; DHL, double-hit lymphoma; Dx, diagnosis; IPI, international prognostic index; LDH, lactate dehydrogenase; mo, months; NA, not available; NR, not reported; PS, performance status; ULN, upper limit normal; y, year.
Figure 1. Outcome of patients with Burkitt leukemia/lymphoma and high-grade B-cell lymphoma treated with hyper-CVAD plus rituximab. Overall survival (A) and relapse-free (B) survival according to disease type. Overall survival (C) and relapse-free survival (D) according to age. Overall survival (E) and relapse-free survival (F) according to the status of baseline CNS disease. Cumulative incidence of relapse according to bone marrow involvement (G) and CNS involvement (H). y.o., years old.
In conclusion, the hyper-CVAD-R regimen is effective in patients with BL and HGBCL and is associated with a low incidence of CNS relapse, even in high-risk patients. Regimens containing high-dose MTX and Ara-C are preferable for patients with higher risk of CNS relapse. CNS relapse is associated with dismal prognosis, indicating a major unmet need.

Authorship

Contribution: B.S. and K.M. analyzed the data and wrote the manuscript; E.J. designed the study and wrote the manuscript; J.D.K. and S.E.H. performed pathological analysis; G.R.-C. analyzed the data; F.R., N.J.S., P.T., N.J., and H.K. collected data and treated patients; E.J., J.K., and H.K. provided leadership and managed the study team; and all authors read and approved the manuscript.

Conflict-of-interest disclosure: E.J. has research grants with Amgen, AbbVie, Spectrum, BMS, Takeda Oncology, Pfizer, and Adaptive. F.R. has had honoraria and has been a member of advisory boards with BMS, Novartis, AbbVie, and Amgen. H.K. reports grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. N.J.S. has served as consultant for Takeda Oncology and AstraZeneca, reports receiving commercial research grants from Takeda Oncology and Astellas Pharma Inc, and has received speakers’ bureau honoraria from Amgen.

Data sharing statement: For data sharing, contact the corresponding author: ejabbour@mdanderson.org.

ORCID profiles: B.S., 0000-0002-8838-9350; J.D.K., 0000-0003-2621-3584

Correspondence: Elias Jabbour, Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: ejabbour@mdanderson.org.

References

1. Habermann TM, Macon WR, Maurer MJ, et al. Treatment and clinical outcomes of high grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (double hit/triple hit lymphomas). Blood. 2016;128(22):155.
2. Landsburg DJ, Falkiewicz MK, Malý J, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol. 2017;35(20):2260-2267.
3. Molyneux EM, Rochford R, Griffin B, et al. Burkitt’s lymphoma. Lancet. 2012;379(9822):1234-1244.
4. Svedlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
5. Evens AM, Carson KR, Kolesar J, et al. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/ IVAC regimen for untreated Burkitt’s lymphoma. Ann Oncol. 2013;24(12):3076-3081.
6. Hoelzer D, Walewski J, Döhner H, et al; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124(26):3870-3879.
7. Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10036):2402-2411.
8. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569-1580.
9. Perry AM, Crockett D, Dave BJ, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: study of 39 cases. Br J Haematol. 2013;162(1):40-49.
10. Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799.
11. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915-1925.
12. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609-e617.
13. Alderuccio JP, Lossos IS. DA-EPOCH-R for adult Burkitt’s lymphoma: pros and cons. J Oncol Pract. 2018;14(11):676-678.
14. Evens AM, Danilov A, Jagadeesh D, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021;137(3):374-386.
15. Svedlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, revised 4th edition. Lyon, France: IARC; 2017.
16. Rausch CR, Jabbour EJ, Kantarjian HM, Kadia TM. Optimizing the use of the hyperCVAD regimen: clinical vignettes and practical management. Cancer. 2020;126(8):1152-1160.
17. Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17(8):2461-2470.
18. Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38(22):2519-2529.
19. Zayac A, Evens AM, Stadnik A, et al. Outcomes of patients with newly-diagnosed Burkitt Lymphoma (BL) and central nervous system (CNS) involvement treated in the modern era: a multi-institutional real-world analysis. Blood. 2019;134(suppl 1):134.
20. Decker DP, Egan PC, Zayac AS, Treaba DO, Olszewski AJ. Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma. *Leuk Lymphoma.* 2020;61(1):198-201.

21. Chu YY, Su NK, Alter S, et al. Therapeutic effects of a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 antibody (2B8T2M) in combination with expanded natural killer cells against rituximab sensitive and resistant Burkitt lymphoma (BL). *Blood.* 2017;130(suppl 1):3587.

22. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. *Leukemia.* 2007;21(11):2240-2245.

23. Gehringer F, Weissinger SE, Möller P, Wirth T, Ushmorov A. Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma. *Leukemia.* 2020;34(3):857-871.

24. Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. *Lancet Oncol.* 2018;19(2):240-248.